Von willebrand factor, ADAMTS13 activity, TNF-α and their relationships in patients with chronic kidney disease

Experimental and Therapeutic Medicine

Volumn 3, Issue 3, 2012, Pages 530-534

  Shen, Lei ^a   Lu, Guoyuan ^a   Dong, Ningzheng ^a   Jiang, Liqiong ^a   Ma, Zhenni ^a   Ruan, Changgeng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Adamts13; Chronic kidney disease; Tumor necrosis factor ; Von Willebrand factor

Indexed keywords

CHOLESTEROL; CREATININE; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IDIOPATHIC NEPHRITIC SYNDROME; INFLAMMATION; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PROTEIN BLOOD LEVEL; THROMBOSIS;

EID: 84855845483     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.432     Document Type: Article

References (26)

1. Ocak G, Verduijn M, Vossen CY, et al: Chronic kidney disease stages 1-3 increase the risk of venous thrombosis. J Thromb Haemost 8: 2428-2435, 2010.
2. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI and Pinkney JH: Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 16: 1189-1197, 2001.
3. Guebre-Egziabher F and Fouque D: Metabolic consequences of inflammation in kidney failure. Nephrologie 24: 383-386, 2003.
4. Patel TV, Mittal BV, Keithi-Reddy SR, Duffield JS and Singh AK: Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract 110: c244-c250, 2008.
5. Lopez-Aguirre Y and Paramo JA: Endothelial cell and hemo-static activation in relation to cytokines in patients with sepsis. Thromb Res 94: 95-101, 1999.
6. Levy GG, Nichols WC, Lian EC, et al: Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413: 488-494, 2001.
7. Nguyen TC, Liu A, Liu L, et al: Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 92: 121-124, 2007.
8. Blann AD: Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 95: 49-55, 2006.
9. Ono T, Mimuro J, Madoiwa S, et al: Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107: 528-534, 2006.
10. Lu GY, Shen L, Wang ZY, Guo XF, Bai X, Su J and Ruan CG: Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases. Chin Med J 121: 133-136, 2008.
11. Spiel AO, Gilbert JC and Jilma B: von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 117: 1449-1459, 2008.
12. Ulloa L and Tracey KJ: The 'cytokine profile': a code for sepsis. Trends Mol Med 11: 56-63, 2005.
13. Hotchkiss RS and Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150, 2003.
14. Bernardo A, Ball C, Nolasco L, Moake JF and Dong JF: Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104: 100-106, 2004.
15. Cao WJ, Niiya M, Zheng XW, Shang DZ and Zheng XL: Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 6: 1233-1235, 2008.
16. Matsukawa M, Kaikita K, Soejima K, et al: Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 100: 758-763, 2007.
17. Claus RA, Bockmeyer CL, Budde U, et al: Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 101: 239-247, 2009.
18. National Kindney Foundation: K/DOQI clinical practice guide-lines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-S266, 2002.
19. Berden JH: Lupus nephritis. Kidney Int 52: 538-558, 1997.
20. Bombardier C, Gladman DD, Urowitz MB, Caron D and Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35: 630-640, 1992.
21. Kokame K, Nobe Y, Kokubo Y, Okayama A and Miyata T: FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129: 93-100, 2005.
22. Del Vecchio GC, Penza R, Altomare M, et al: Cytokine pattern and endothelium damage markers in Henoch-Schonlein purpura. Immunopharmacol Immunotoxicol 30: 623-629, 2008.
23. Kobayashi T, Wada H, Nishioka N, et al: ADAMTS13 related markers and von Willebrand factor in plasma from patients with thrombotic microangiopathy (TMA). Thromb Res 121: 849-854, 2008.
24. Silveira A M, Sjoberg S, Blomback M and Ostman J: von Willebrand factor antigen in plasma and urine in patients with type I (insulin-dependent) diabetes mellitus with and without nephropathy. J Diabetes Complications 6: 89-95, 1992.
25. Kremer Hovinga JA, Zeerleder S, Kessler P, et al: ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 5: 2284-2290, 2007.
26. Nadar SK, Al Yemeni E, Blann AD and Lip GY: Thrombomodulin, von Willebrand factor and E-selectin as plasma markers of endothelial damage/dysfunction and activation in pregnancy induced hypertension. Thromb Res 113: 123-128, 2004.